Literature DB >> 17899313

Danon disease presenting with dilated cardiomyopathy and a complex phenotype.

Matthew R G Taylor1,2, Lisa Ku3, Dobromir Slavov3, Jean Cavanaugh4, Mark Boucek4, Xiao Zhu3, Sharon Graw3, Elisa Carniel3, Carl Barnes3, Dianna Quan3, Ryan Prall3, Mark A Lovell4, Gary Mierau4, Patsy Ruegg3, Naresh Mandava3, Michael R Bristow3, Jeffrey A Towbin5, Luisa Mestroni3.   

Abstract

X-linked dilated cardiomyopathy (XLCM) was first described in 1987 and associated with dystrophin gene (DMD) mutations a decade later in one of the original two families. Here we report long-term follow-up of the second family (XLCM-2), for which a DMD mutation was never found. Analysis of the lysosome-associated membrane protein-2 (LAMP-2) gene detected a novel mutation, confirming a diagnosis of Danon disease. The broad phenotype in this family included dilated and hypertrophic cardiomyopathy, cardiac pre-excitation, skeletal myopathy with high serum creatinine kinase, cognitive impairement (in males), and and a pigmentary retinopathy in affected females. Cardiac biopsy in a 13-month-old mutation-carrying male showed no vacuolization by standard histology. We conclude that XLCM may be the presenting sign of Danon disease and, in the presence of familial history of HCM, pre-excitation, skeletal muscle involvement and retinal pigmentary dystrophy should prompt LAMP-2 clinical testing. Furthermore, the absence of vacuolar myopathy in biopsies from young patients may not exclude Danon disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899313     DOI: 10.1007/s10038-007-0184-8

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  19 in total

Review 1.  Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy.

Authors:  L Mestroni; B Maisch; W J McKenna; K Schwartz; P Charron; C Rocco; F Tesson; A Richter; A Wilke; M Komajda
Journal:  Eur Heart J       Date:  1999-01       Impact factor: 29.983

2.  Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children.

Authors:  Zhao Yang; Colin J McMahon; Liana R Smith; Jeathrina Bersola; Adekunle M Adesina; John P Breinholt; Debra L Kearney; William J Dreyer; Susan W Denfield; Jack F Price; Michelle Grenier; Naomi J Kertesz; Sarah K Clunie; Susan D Fernbach; James F Southern; Stuart Berger; Jeffrey A Towbin; Karla R Bowles; Neil E Bowles
Journal:  Circulation       Date:  2005-09-06       Impact factor: 29.690

3.  Cardiac arrhythmias and the adult form of type II glycogenosis.

Authors:  M Francesconi; E Auff
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

4.  Lysosomal glycogen storage disease with normal acid maltase.

Authors:  M J Danon; S J Oh; S DiMauro; J R Manaligod; A Eastwood; S Naidu; L H Schliselfeld
Journal:  Neurology       Date:  1981-01       Impact factor: 9.910

5.  [WPW syndrome combined with AV block 2 in an adult with glycogenosis (Type II)].

Authors:  M Francesconi; E Auff; C Ursin; E Sluga
Journal:  Wien Klin Wochenschr       Date:  1982-08-06       Impact factor: 1.704

6.  Characterization of Danon disease in a male patient and his affected mother.

Authors:  Kazuma Sugie; Tateo Koori; Ayaka Yamamoto; Megumu Ogawa; Michio Hirano; Kiyoharu Inoue; Ikuya Nonaka; Ichizo Nishino
Journal:  Neuromuscul Disord       Date:  2003-11       Impact factor: 4.296

7.  Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy.

Authors:  Michael Arad; Ivan P Moskowitz; Vickas V Patel; Ferhaan Ahmad; Antonio R Perez-Atayde; Douglas B Sawyer; Mark Walter; Guo H Li; Patrick G Burgon; Colin T Maguire; David Stapleton; Joachim P Schmitt; X X Guo; Anne Pizard; Sabina Kupershmidt; Dan M Roden; Charles I Berul; Christine E Seidman; J G Seidman
Journal:  Circulation       Date:  2003-06-02       Impact factor: 29.690

Review 8.  Clinicopathological features of genetically confirmed Danon disease.

Authors:  K Sugie; A Yamamoto; K Murayama; S J Oh; M Takahashi; M Mora; J E Riggs; J Colomer; C Iturriaga; A Meloni; C Lamperti; S Saitoh; E Byrne; S DiMauro; I Nonaka; M Hirano; I Nishino
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

9.  X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus.

Authors:  J A Towbin; J F Hejtmancik; P Brink; B Gelb; X M Zhu; J S Chamberlain; E R McCabe; M Swift
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690

10.  Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease.

Authors:  Marina Fanin; Anna C Nascimbeni; Luigi Fulizio; Marco Spinazzi; Paola Melacini; Corrado Angelini
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

View more
  17 in total

1.  LAMP2 microdeletions in patients with Danon disease.

Authors:  Zhao Yang; Birgit H Funke; Linda H Cripe; G Wesley Vick; Debora Mancini-Dinardo; Liana S Peña; Ronald J Kanter; Brenda Wong; Brandy H Westerfield; Jaquelin J Varela; Yuxin Fan; Jeffrey A Towbin; Matteo Vatta
Journal:  Circ Cardiovasc Genet       Date:  2010-02-20

2.  Danon Disease Due to a Novel LAMP2 Microduplication.

Authors:  Matthew A Lines; Stacy Hewson; William Halliday; Peter J B Sabatini; Tracy Stockley; Anne I Dipchand; Sarah Bowdin; Komudi Siriwardena
Journal:  JIMD Rep       Date:  2013-11-13

Review 3.  Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy.

Authors:  Teisha J Rowland; Mary E Sweet; Luisa Mestroni; Matthew R G Taylor
Journal:  J Cell Sci       Date:  2016-05-10       Impact factor: 5.285

4.  Danon disease: intrafamilial phenotypic variability related to a novel LAMP-2 mutation.

Authors:  Sarah-Louise Cottinet; Anne-Marie Bergemer-Fouquet; Annick Toutain; Frédérique Sabourdy; Zoha Maakaroun-Vermesse; Thierry Levade; Alain Chantepie; François Labarthe
Journal:  J Inherit Metab Dis       Date:  2010-12-16       Impact factor: 4.982

Review 5.  Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies.

Authors:  Babken Asatryan; Argelia Medeiros-Domingo
Journal:  J Mol Med (Berl)       Date:  2018-08-20       Impact factor: 4.599

6.  Functional performance and muscle strength phenotypes in men and women with Danon disease.

Authors:  Jennifer E Stevens-Lapsley; Laurel R Kramer; Jaclyn E Balter; Jean Jirikowic; Dana Boucek; Matthew Taylor
Journal:  Muscle Nerve       Date:  2010-12       Impact factor: 3.217

7.  Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion.

Authors:  Stephanie Duguez; William Duddy; Helen Johnston; Jeanne Lainé; Marie Catherine Le Bihan; Kristy J Brown; Anne Bigot; Yetrib Hathout; Gillian Butler-Browne; Terence Partridge
Journal:  Cell Mol Life Sci       Date:  2013-01-24       Impact factor: 9.261

Review 8.  Danon disease: clinical features, evaluation, and management.

Authors:  Ryan S D'souza; Cecilia Levandowski; Dobromir Slavov; Sharon L Graw; Larry A Allen; Eric Adler; Luisa Mestroni; Matthew R G Taylor
Journal:  Circ Heart Fail       Date:  2014-09       Impact factor: 8.790

Review 9.  Mapping autophagy on to your metabolic radar.

Authors:  Eijiro Yamada; Rajat Singh
Journal:  Diabetes       Date:  2012-02       Impact factor: 9.461

10.  Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy.

Authors:  Barry J Maron; William C Roberts; Michael Arad; Tammy S Haas; Paolo Spirito; Gregory B Wright; Adrian K Almquist; Jeanne M Baffa; J Philip Saul; Carolyn Y Ho; Jonathan Seidman; Christine E Seidman
Journal:  JAMA       Date:  2009-03-25       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.